Inhibikase Therapeutics, Inc.
IKT
$2.37
$0.010.42%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | -19.57M | -18.38M | -19.20M | -19.03M | -19.13M |
Total Depreciation and Amortization | 26.40K | 26.40K | 179.00K | 177.40K | 175.80K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 368.60K | 367.70K | 461.80K | 531.70K | 474.70K |
Change in Net Operating Assets | 1.93M | 1.52M | 2.58M | 234.70K | 280.40K |
Cash from Operations | -17.24M | -16.47M | -15.98M | -18.09M | -18.20M |
Capital Expenditure | 0.00 | 0.00 | -14.20K | -14.20K | -14.20K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -358.10K | 14.18M | 14.20M | 11.67M | 18.75M |
Cash from Investing | -358.10K | 14.18M | 14.18M | 11.66M | 18.74M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | 0.00 |
Issuance of Common Stock | 3.79M | 3.61M | 398.20K | 8.58M | 8.58M |
Repurchase of Common Stock | -- | -- | -36.00K | -36.00K | -36.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -138.60K | -138.60K | -169.20K | -138.60K | -- |
Cash from Financing | 3.66M | 3.47M | 193.00K | 8.41M | 8.54M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -13.95M | 1.18M | -1.60M | 1.98M | 9.08M |